Does the media prefer BEAM or PRME?

In the previous week, Beam Therapeutics and Beam Therapeutics both had 5 articles in the media. Beam Therapeutics' average media sentiment score of 1.17 beat Prime Medicine's score of 0.90 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, PRME or ADMA?

ADMA Biologics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prime Medicine $4.63M 132.80 -$201.14M -$1.06 N/A ADMA Biologics $512.28M 4.30 $146.93M $0.70 14.06

Does the media favor PRME or ADMA?

In the previous week, Prime Medicine and Prime Medicine both had 5 articles in the media. Prime Medicine's average media sentiment score of 0.90 beat ADMA Biologics' score of 0.15 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PHVS or PRME more profitable?

Pharvaris has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Pharvaris' return on equity of -61.40% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Prime Medicine -4,613.11% -188.27% -59.11%

Does the media refer more to PHVS or PRME?

In the previous week, Pharvaris had 12 more articles in the media than Prime Medicine. MarketBeat recorded 17 mentions for Pharvaris and 5 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.90 beat Pharvaris' score of 0.05 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Prime Medicine 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PRME or VCEL?

Vericel has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prime Medicine $4.63M 132.80 -$201.14M -$1.06 N/A Vericel $276.26M 7.91 $16.52M $0.47 90.81

Is PRME or VCEL more profitable?

Vericel has a net margin of 7.91% compared to Prime Medicine's net margin of -4,613.11%. Vericel's return on equity of 6.91% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Prime Medicine -4,613.11% -188.27% -59.11% Vericel 7.91% 6.91% 5.02%

Does the media prefer PRME or VCEL?

In the previous week, Vericel had 3 more articles in the media than Prime Medicine. MarketBeat recorded 8 mentions for Vericel and 5 mentions for Prime Medicine. Vericel's average media sentiment score of 1.54 beat Prime Medicine's score of 0.90 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to NUVB or PRME?

In the previous week, Nuvation Bio had 9 more articles in the media than Prime Medicine. MarketBeat recorded 14 mentions for Nuvation Bio and 5 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.90 beat Nuvation Bio's score of 0.46 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prime Medicine (PRME) Competitors

$3.39 +0.15 (+4.63%)

As of 08/21/2026 04:00 PM Eastern

Compare

PRME vs. BEAM, ADMA, PHVS, VCEL, and NUVB

Should you buy Prime Medicine stock or one of its competitors? Prime Medicine's main competitors and comparable companies include Beam Therapeutics (BEAM), ADMA Biologics (ADMA), Pharvaris (PHVS), Vericel (VCEL), and Nuvation Bio (NUVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prime Medicine compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Beam Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market.

Beam Therapeutics has a net margin of -54.75% compared to Prime Medicine's net margin of -4,613.11%. Beam Therapeutics' return on equity of -30.71% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

In the previous week, Beam Therapeutics and Beam Therapeutics both had 5 articles in the media. Beam Therapeutics' average media sentiment score of 1.17 beat Prime Medicine's score of 0.90 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.00	-$79.99M	-$0.86	N/A
Prime Medicine	$4.63M	132.80	-$201.14M	-$1.06	N/A

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 16.0% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Beam Therapeutics currently has a consensus target price of $49.00, suggesting a potential upside of 64.65%. Prime Medicine has a consensus target price of $7.69, suggesting a potential upside of 126.97%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Beam Therapeutics beats Prime Medicine on 9 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to ADMA Biologics?

Prime Medicine (NASDAQ:PRME) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Prime Medicine has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

ADMA Biologics has a net margin of 32.98% compared to Prime Medicine's net margin of -4,613.11%. ADMA Biologics' return on equity of 40.17% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
ADMA Biologics	32.98%	40.17%	26.97%

In the previous week, Prime Medicine and Prime Medicine both had 5 articles in the media. Prime Medicine's average media sentiment score of 0.90 beat ADMA Biologics' score of 0.15 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 3.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ADMA Biologics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	132.80	-$201.14M	-$1.06	N/A
ADMA Biologics	$512.28M	4.30	$146.93M	$0.70	14.06

Prime Medicine presently has a consensus target price of $7.69, indicating a potential upside of 126.97%. ADMA Biologics has a consensus target price of $18.67, indicating a potential upside of 89.70%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Prime Medicine and ADMA Biologics tied by winning 8 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Pharvaris has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Pharvaris' return on equity of -61.40% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

In the previous week, Pharvaris had 12 more articles in the media than Prime Medicine. MarketBeat recorded 17 mentions for Pharvaris and 5 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.90 beat Pharvaris' score of 0.05 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Prime Medicine	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has a beta of -2.31, meaning that its share price is 331% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

Pharvaris currently has a consensus target price of $51.08, indicating a potential upside of 40.82%. Prime Medicine has a consensus target price of $7.69, indicating a potential upside of 126.97%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

70.4% of Prime Medicine shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by insiders. Comparatively, 16.0% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pharvaris has higher earnings, but lower revenue than Prime Medicine. Pharvaris is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Prime Medicine	$4.63M	132.80	-$201.14M	-$1.06	N/A

Summary

Prime Medicine beats Pharvaris on 9 of the 15 factors compared between the two stocks.

How does Prime Medicine compare to Vericel?

Prime Medicine (NASDAQ:PRME) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Vericel has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	132.80	-$201.14M	-$1.06	N/A
Vericel	$276.26M	7.91	$16.52M	$0.47	90.81

Vericel has a net margin of 7.91% compared to Prime Medicine's net margin of -4,613.11%. Vericel's return on equity of 6.91% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Vericel	7.91%	6.91%	5.02%

In the previous week, Vericel had 3 more articles in the media than Prime Medicine. MarketBeat recorded 8 mentions for Vericel and 5 mentions for Prime Medicine. Vericel's average media sentiment score of 1.54 beat Prime Medicine's score of 0.90 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Prime Medicine has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Vericel has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Prime Medicine presently has a consensus price target of $7.69, indicating a potential upside of 126.97%. Vericel has a consensus price target of $58.40, indicating a potential upside of 36.83%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

70.4% of Prime Medicine shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by insiders. Comparatively, 7.6% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vericel beats Prime Medicine on 9 of the 17 factors compared between the two stocks.

How does Prime Medicine compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Prime Medicine has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	38.63	-$204.63M	-$0.44	N/A
Prime Medicine	$4.63M	132.80	-$201.14M	-$1.06	N/A

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market.

In the previous week, Nuvation Bio had 9 more articles in the media than Prime Medicine. MarketBeat recorded 14 mentions for Nuvation Bio and 5 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.90 beat Nuvation Bio's score of 0.46 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio presently has a consensus price target of $13.00, suggesting a potential upside of 87.86%. Prime Medicine has a consensus price target of $7.69, suggesting a potential upside of 126.97%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Nuvation Bio has a net margin of -88.18% compared to Prime Medicine's net margin of -4,613.11%. Nuvation Bio's return on equity of -46.59% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

Summary

Prime Medicine beats Nuvation Bio on 9 of the 17 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRME vs. The Competition

Export

Metric	Prime Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$614.87M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-3.20	11.62	272.60	24.24
Price / Sales	132.80	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	15.41	16.80	13.05	6.20
Net Income	-$201.14M	-$12.50M	$3.47B	$348.59M
7 Day Performance	9.71%	3.29%	2.09%	0.08%
1 Month Performance	14.14%	8.23%	6.64%	3.88%
1 Year Performance	N/A	55.05%	25.02%	16.98%

Prime Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRME Prime Medicine	3.0525 of 5 stars	$3.39 +4.6%	$7.69 +127.0%	N/A	$614.87M	$4.63M	N/A	N/A	Analyst Forecast
BEAM Beam Therapeutics	2.1691 of 5 stars	$26.85 -1.6%	$49.00 +82.5%	+78.8%	$2.82B	$156.04M	N/A	510	Positive News
ADMA ADMA Biologics	3.9153 of 5 stars	$9.90 +1.5%	$18.67 +88.6%	-44.7%	$2.26B	$510.17M	14.14	530
PHVS Pharvaris	3.691 of 5 stars	$34.42 -1.2%	$50.08 +45.5%	+56.9%	$2.25B	N/A	N/A	30	Analyst Revision
VCEL Vericel	4.2311 of 5 stars	$44.35 +0.9%	$58.40 +31.7%	+15.3%	$2.25B	$276.26M	94.36	300	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRME) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prime Medicine (PRME) Competitors

PRME vs. BEAM, ADMA, PHVS, VCEL, and NUVB

How does Prime Medicine compare to Beam Therapeutics?

Summary

How does Prime Medicine compare to ADMA Biologics?

Summary

How does Prime Medicine compare to Pharvaris?

Summary

How does Prime Medicine compare to Vericel?

Summary

How does Prime Medicine compare to Nuvation Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prime Medicine (PRME) Competitors

PRME vs. BEAM, ADMA, PHVS, VCEL, and NUVB

How does Prime Medicine compare to Beam Therapeutics?

Which has more volatility and risk, BEAM or PRME?

Is BEAM or PRME more profitable?

Does the media prefer BEAM or PRME?

Which has better valuation and earnings, BEAM or PRME?

Do institutionals & insiders have more ownership in BEAM or PRME?

Do analysts rate BEAM or PRME?

Summary

How does Prime Medicine compare to ADMA Biologics?

Which has more volatility and risk, PRME or ADMA?

Is PRME or ADMA more profitable?

Does the media favor PRME or ADMA?

Do insiders and institutionals believe in PRME or ADMA?

Which has preferable valuation & earnings, PRME or ADMA?

Do analysts prefer PRME or ADMA?

Summary

How does Prime Medicine compare to Pharvaris?

Is PHVS or PRME more profitable?

Does the media refer more to PHVS or PRME?

Which has more risk & volatility, PHVS or PRME?

Do analysts recommend PHVS or PRME?

Do insiders & institutionals have more ownership in PHVS or PRME?

Which has preferable valuation & earnings, PHVS or PRME?

Summary

How does Prime Medicine compare to Vericel?

Which has better earnings & valuation, PRME or VCEL?

Is PRME or VCEL more profitable?

Does the media prefer PRME or VCEL?

Which has more risk & volatility, PRME or VCEL?

Do analysts prefer PRME or VCEL?

Do institutionals & insiders believe in PRME or VCEL?

Summary

How does Prime Medicine compare to Nuvation Bio?

Which has better earnings & valuation, NUVB or PRME?

Do institutionals and insiders hold more shares of NUVB or PRME?

Which has more volatility & risk, NUVB or PRME?

Does the media refer more to NUVB or PRME?

Do analysts rate NUVB or PRME?

Is NUVB or PRME more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools